Page last updated: 2024-08-17

adenosine monophosphate and ticagrelor

adenosine monophosphate has been researched along with ticagrelor in 74 studies

Research

Studies (74)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (21.62)	29.6817
2010's	50 (67.57)	24.3611
2020's	8 (10.81)	2.80

Authors

Authors	Studies
Humphries, RG; van Giezen, JJ	1
Gurbel, PA; Tantry, US	1
Cattaneo, M	3
Rich, JD; Wiviott, SD	1
Angiolillo, DJ	1
Barker, CM; Price, MJ	1
Angiolillo, DJ; Capranzano, P	1
Angiolillo, DJ; Guzman, LA	1
Eikelboom, JW; Hirsh, J; Raju, NC	1
Akram, F; Akram, S; Postuła, M	1
Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK	1
Butt, M; Lip, GY; Shantsila, E; Siddique, A	1
Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS	1
Franchini, M; Mannucci, PM	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
del Río, A; Heras, M	1
Jilma, B; Krumphuber, J; Siller-Matula, JM	1
Cattaneo, M; Podda, GM	1
Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; Nylander, S; van Giezen, H; White, AE	1
Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE	1
Frey, N; Ivandic, B	1
Ağırbaşlı, M; Cinçin, A; Güvenç, H	1
Storey, RF	1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J	1
Cattaneo, GJ; Cattaneo, M; Podda, GM	1
Moliterno, DJ; Rajan, L	1
Böhm, M; Schirmer, SH	1
Contractor, H; Ruparelia, N	1
Lavi, R; Lavi, S	1
Barn, K; Steinhubl, SR	1
Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J	1
Bernlochner, I; Sibbing, D	1
Augoustides, JG; Lane, B; Patel, PA	1
Alhammouri, A; Cohen, MV; Cui, L; Downey, JM; Yang, XM	1
Alves, CM; Caixeta, AM; Carvalho, AC; Carvalho, L; Chan, M; Falcão, FJ	1
Aylward, PE; Sinhal, AR	1
DiNicolantonio, JJ; Serebruany, VL; Sibbing, D	1
Jover, E; Tello-Montoliu, A; Valdés, M	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Sabouret, P; Taiel-Sartral, M	1
Agarwal, Z; Gogo, P; Keating, FK; Schneider, DJ; Seecheran, N	1
Caldeira, D; Ferreira, JJ; Pinto, FJ	1
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P	1
Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L	1
Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M	1
Basabe-Desmonts, L; Gilmartin, N; Jose, B; Kenny, D; Kent, NJ; McCluskey, P; Ricco, AJ; Somers, M	1
Angiolillo, DJ; Capodanno, D	1
Drebes, A; Klonaris, C; Liakakos, T; Matheiken, S; Patelis, N	1
Bhatt, DL; Fuster, V; Gersh, BJ; Lennon, RJ; Narula, J; Rihal, CS; Singh, M; Stone, GW	1
Andell, P; Erlinge, D; Götberg, M; James, S; Koul, S; Mohammad, MA; Scherstén, F	1
Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC	1
Frelinger, AL; Gerrits, AJ; Jakubowski, JA; Michelson, AD; Sugidachi, A	1
Amann, M; Bömicke, T; Ferenc, M; Hauschke, D; Hochholzer, W; Kleiner, P; Löffelhardt, N; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM; Younas, I	1
Gillard, M; Gomeza, J; Hennen, S; Kostenis, E; Merten, N; Mohr, K; Peters, L; Preis, P; Schmitt, NK; Schrage, R; Schröder, R; Simon, K; Vermeiren, C	1
Angiolillo, DJ; Bass, TA; Been, L; Cho, JR; Faz, G; Franchi, F; Kureti, M; Park, Y; Rollini, F; Thano, E	1
Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM	1
Cetran, L; Coste, P; Fiore, M; Gerbaud, E; Marchand, H; Seguy, B	1
Calnan, MW; Crawford, AN	1
Alexopoulos, D; Didagelos, M; Iliodromitis, E; Karvounis, H; Kikas, P; Pappas, C; Sfantou, D; Tziakas, D; Xanthopoulou, I; Ziakas, A	1
Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM	1
Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kaufman, M; Nawaz, A; Pineda, AM; Rivas, A; Rollini, F; Shaikh, Z; Silva, G; Smairat, R; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM	1
Capodanno, D; Capranzano, P	1
Erlinge, D	1
Armesilla, AL; Berry, C; Cotton, JM; Ford, TJ; Hothi, SS; Khan, N; Khogali, SS; Martins, J; McAlindon, EJ; Munir, S; Murray, HM; Thomas, MR; Townend, JN; Ubaid, S; Wrigley, B	1
Alexopoulos, D; Lianos, I; Mpahara, A; Varlamos, C	1
Finniss, M; Helton, T; Khalid, M; Khan, AA; Murtaza, G	1
Brassart-Pasco, S; Djerada, Z; Feliu, C; Millart, H; Nguyen, P; Oszust, F; Peyret, H; Poitevin, G	1
Dabus, G; Linfante, I; Ravipati, K; Reyes, D; Starosciak, AK	1
Abdel-Latif, A; Abo-Aly, M; Chelvarajan, L; El-Helw, M; George, B; Shokri, E; Smyth, SS; Ziada, K	1
Agostini, C; Bernardo, P; Caniato, F; Cappelli, F; Di Filippo, C; Di Mario, C; Mattesini, A; Meucci, F; Sori, A; Stolcova, M	1
Angiolillo, DJ; Bhatt, DL; Davidson-Ray, L; Dell'Anna, C; Diaz, M; Edwards, L; El-Sabae, H; Garratt, KN; Ohman, EM; Rymer, JA; Salahuddin, K; Tasissa, G; Waksman, R; Wang, TY; Washam, JB	1
Baber, U	1

Reviews

46 review(s) available for adenosine monophosphate and ticagrelor

Article	Year
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Animals; Arterial Occlusive Diseases; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Rabbits; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor	2005
Aspirin and clopidogrel resistance: consideration and management. Journal of interventional cardiology, 2006, Volume: 19, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2006
Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine	2007
New antiplatelet therapies for acute coronary syndromes. Current cardiology reports, 2007, Volume: 9, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome	2007
ADP receptor antagonism: what's in the pipeline? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2007
Pharmacology of emerging novel platelet inhibitors. American heart journal, 2008, Volume: 156, Issue:2 Suppl Topics: Adenosine; Adenosine Monophosphate; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor	2008
Clinical overview of promising nonthienopyridine antiplatelet agents. American heart journal, 2008, Volume: 156, Issue:2 Suppl Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor	2008
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2008
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases. Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2009
Advances in antiplatelet therapy: agents in clinical development. The American journal of cardiology, 2009, Feb-02, Volume: 103, Issue:3 Suppl Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome	2009
New antiplatelet drugs: beyond aspirin and clopidogrel. International journal of clinical practice, 2009, Volume: 63, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Emerging P2Y12 receptor antagonists: role in coronary artery disease. Current vascular pharmacology, 2010, Volume: 8, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor	2010
New P2Y12 blockers. Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Treatment Outcome	2009
New antiplatelet agents: why they are needed. European journal of internal medicine, 2009, Volume: 20, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor	2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor	2010
State of the art of new P2Y12 antagonists. Internal and emergency medicine, 2010, Volume: 5, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2010
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Novel agents in antiplatelet therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2010
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2011
[Myocardial infarction: Role of new antiplatelet agents]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors	2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]. Recenti progressi in medicina, 2011, Volume: 102, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
[Update on anti-platelet therapy]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor	2011
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery. Journal of cardiothoracic and vascular anesthesia, 2012, Volume: 26, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Thienopyridines and other ADP-receptor antagonists. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2012
Progress in platelet blockers: the target is the P2Y12 receptor. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor	2013
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology, 2014, Volume: 127, Issue:1 Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction	2014
[New antiplatelet drugs in coronary artery disease]. Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11 Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2014
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin	2014
Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of diabetes research, 2016, Volume: 2016 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents. Current pharmaceutical design, 2016, Volume: 22, Issue:29 Topics: Adenosine; Adenosine Monophosphate; Imines; Lactones; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Quinazolinones; Sulfonamides; Ticagrelor	2016
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic proceedings, 2016, Volume: 91, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Antithrombins; Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor	2016
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Switching between P2Y Vascular pharmacology, 2019, Volume: 116 Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome	2019
P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes. Expert review of cardiovascular therapy, 2019, Volume: 17, Issue:10 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor	2019

Trials

8 trial(s) available for adenosine monophosphate and ticagrelor

Article	Year
Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Vermont	2014
Randomized Comparison of Oral P2Y JACC. Cardiovascular interventions, 2017, 01-23, Volume: 10, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Drug Substitution; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y JACC. Cardiovascular interventions, 2017, 07-10, Volume: 10, Issue:13 Topics: Adenosine Monophosphate; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Synergism; Humans; Microfilament Proteins; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor; Time Factors	2017
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor. Thrombosis and haemostasis, 2018, Volume: 118, Issue:2 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor	2018
Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2018, 10-02, Volume: 72, Issue:14 Topics: Adenosine Monophosphate; Blood Platelets; Drug Therapy, Combination; Humans; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor	2018
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2019, 04-02, Volume: 139, Issue:14 Topics: Adenosine Monophosphate; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Double-Blind Method; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome	2019
Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thrombosis and haemostasis, 2019, Volume: 119, Issue:7 Topics: Adenosine Monophosphate; Aged; Blood Platelets; Blood Vessels; Cells, Cultured; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardium; Percutaneous Coronary Intervention; Platelet Activation; Platelet Function Tests; Receptors, Purinergic P2Y12; Regional Blood Flow; Ticagrelor	2019
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction. Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:3 Topics: Adenosine Monophosphate; Contrast Media; Gadolinium; Humans; Pancreatic Elastase; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome	2021

Other Studies

20 other study(ies) available for adenosine monophosphate and ticagrelor

Article	Year
Antiplatelet therapy in acute coronary syndromes. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2008
Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function. Thrombosis and haemostasis, 2011, Volume: 105, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, G-Protein-Coupled; Thiophenes; Ticagrelor	2011
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:2 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor	2011
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thrombosis research, 2012, Volume: 130, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Animals; Blood Platelets; Clopidogrel; Dogs; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2012
Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Guanidines; Hypothermia, Induced; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Sulfones; Ticagrelor	2013
P2Y12 platelet receptors: importance in percutaneous coronary intervention. Arquivos brasileiros de cardiologia, 2013, Volume: 101, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Thiophenes; Ticagrelor	2013
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs. Langmuir : the ACS journal of surfaces and colloids, 2016, Mar-22, Volume: 32, Issue:11 Topics: Abciximab; Adenosine; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Cattle; Clopidogrel; Dimethylpolysiloxanes; Equipment Design; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Powders; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Serum Albumin, Bovine; Ticagrelor; Ticlopidine	2016
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets, 2017, Volume: 28, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor	2017
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Humans; Kinetics; Microfilament Proteins; P-Selectin; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor	2017
The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes. Molecular pharmacology, 2017, Volume: 91, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Animals; Cell Membrane; CHO Cells; Cricetinae; Cricetulus; Cysteine; HEK293 Cells; Humans; Leukotrienes; Ligands; Mice; Nerve Tissue Proteins; Rats; Receptors, G-Protein-Coupled; Signal Transduction; Small Molecule Libraries; Ticagrelor; Uracil Nucleotides	2017
Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention. Resuscitation, 2018, Volume: 130 Topics: Adenosine Monophosphate; Biological Availability; Coma; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome	2018
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy. Journal of pharmacy practice, 2020, Volume: 33, Issue:2 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor	2020
Effect of P2Y Thrombosis research, 2019, Volume: 173 Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor	2019
Cangrelor for ST-Segment-Elevation Myocardial Infarction. Circulation, 2019, 04-02, Volume: 139, Issue:14 Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Ticagrelor	2019
Efficacy of Cangrelor as Bridging Therapy Post PCI. Cardiovascular & hematological disorders drug targets, 2020, Volume: 20, Issue:3 Topics: Adenosine Monophosphate; Aged; Aspirin; Colectomy; Colonic Neoplasms; Drug-Eluting Stents; Factor Xa Inhibitors; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Thrombosis; Ticagrelor	2020
Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of Hypoxia. Biomolecules, 2020, 05-09, Volume: 10, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Apoptosis; Biomarkers; Cell Hypoxia; Extracellular Space; Human Umbilical Vein Endothelial Cells; Humans; Nitric Oxide Synthase; Phosphatidylinositol 3-Kinases; Prostaglandin-Endoperoxide Synthases; Receptors, Purinergic P1; RNA, Messenger; Signal Transduction; Stress, Physiological; Ticagrelor	2020
Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. Journal of neurointerventional surgery, 2021, Volume: 13, Issue:1 Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Female; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Self Expandable Metallic Stents; Stroke; Subarachnoid Hemorrhage; Ticagrelor; Treatment Outcome	2021
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty. Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 04-01, Volume: 22, Issue:4 Topics: Adenosine Monophosphate; Aged; Anxiety; Chest Pain; Coronary Angiography; Coronary Occlusion; Drug Substitution; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Electrocardiography; Humans; Inferior Wall Myocardial Infarction; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; Withholding Treatment	2021
Cangrelor Use Patterns and Transition to Oral P2Y Journal of the American Heart Association, 2022, 06-07, Volume: 11, Issue:11 Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome	2022
Switching Between Intravenous and Oral P2Y JACC. Cardiovascular interventions, 2023, 01-09, Volume: 16, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome	2023